Tax management strategy
As one of the largest tree farming managers in Australia, ITC is focused 100% on forestry. ITC's product structure is unique. All fees after initial establishment in the Pulpwood and Indian Sandalwood projects, may be paid as a fixed percentage of harvest proceeds which totally align ITC's interests with investors. That is, if ITC does not perform, they don't get paid. Now with the backing of Futuris (Market cap exceeds $1 billion), ITC offers sound returns from investing in sustainable tree farming, a proposition supported by the high recommendation of independent research groups. ATO product ruling confirms 100% tax deductibility. Investment options, research reports and the ITC 2004 PDS (offer document) are accessible here or phone us on 1300 880 160.
Any potential tax advantages for 2003/2004 would only be available to investors who invest prior to 30 June 2004.
Moby Oil & Gas Ltd
IPO/Float closing on the 7th July 2004
Oil and gas exploration is a high-risk activity; there is no certainty that Moby's exploration programs will be successful. However, particularly with respect to their interests in the Gippsland Basin, they are encouraged by the strategic location and assessed prospectively of their permits, the extent of nearby developments, the activity going on around them and by their location in a proven hydrocarbon-producing province.
To invest in the Moby offer please click here to obtain or download a prospectus. Applications for a minimum of $2,000 at $1 per share need to be made before the offer close date, 7th July 2004.
BioPharmica - commercialising cancer research
IPO/Float expected to close on the 5th July 2004
BioPharmica is working with its partners to commercialise cancer research into the detection and treatment of breast, prostate and colorectal cancers. BioPharmica intend to commercialise research into HLS5. In recognition of it's potential in detecting and treating cancer; HLS5 has attracted over $1M in research funding from the NHMRC, Cancer Council of WA, the National Breast Cancer Foundation and the Medical Research Foundation of Royal Perth Hospital.
The minimum investment is $2,000 and the offer is expected to close on or before 5th July 2004. Click here to find out more information and to order your copy of the prospectus.
We have yet to be paid commissions for the OM-IP 140 Plus. As soon as these are paid to us, investors who participated in this offer will receive a cheque for the 4% sales commission. You should expect this within the next two weeks.
The InvestSMART Team